Publicaciones (32) Publicaciones de MARIA PILAR GONZALEZ CABO

2024

  1. Persistent Pulmonary Fibrotic Sequelae in Patients With Telomere Shortening One Year After Severe COVID-19

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 62-64

2022

  1. Frataxin Deficit Leads to Reduced Dynamics of Growth Cones in Dorsal Root Ganglia Neurons of Friedreich’s Ataxia YG8sR Model: A Multilinear Algebra Approach

    Frontiers in Molecular Neuroscience, Vol. 15

  2. Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases?

    Antioxidants, Vol. 11, Núm. 1

2021

  1. Cofilin and neurodegeneration: New functions for an old but gold protein

    Brain Sciences, Vol. 11, Núm. 7

  2. Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies

    Translational Research, Vol. 229, pp. 135-141

  3. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia

    Neurobiology of Disease, Vol. 148

  4. Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms

    Current protein & peptide science, Vol. 22, Núm. 9, pp. 675-694

2020

  1. Antioxidant therapies and oxidative stress in friedreich´s ataxia: The right path or just a diversion?

    Antioxidants, Vol. 9, Núm. 8, pp. 1-23

  2. Cofilin dysregulation alters actin turnover in frataxin-deficient neurons

    Scientific Reports, Vol. 10, Núm. 1

  3. Much More Than a Scaffold: Cytoskeletal Proteins in Neurological Disorders

    Cells, Vol. 9, Núm. 2

  4. Oxidative stress modulates rearrangement of endoplasmic reticulum-mitochondria contacts and calcium dysregulation in a Friedreich's ataxia model

    Redox Biology, Vol. 37

  5. Thioredoxin and glutaredoxin systems as potential targets for the development of new treatments in Friedreich’s ataxia

    Antioxidants, Vol. 9, Núm. 12, pp. 1-25

2019

  1. Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich’s Ataxia Mouse Model

    Neurotherapeutics, Vol. 16, Núm. 2, pp. 432-449

  2. The role of iron in Friedreich's ataxia: Insights from studies in human tissues and cellular and animal models

    Frontiers in Neuroscience, Vol. 13, Núm. FEB

2017

  1. Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich's ataxia patients

    Scientific Reports, Vol. 7, Núm. 1

  2. Reversible axonal dystrophy by calcium modulation in frataxin-deficient sensory neurons of YG8R mice

    Frontiers in Molecular Neuroscience, Vol. 10

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. Two different pathogenic mechanisms, dying-back axonal neuropathy and pancreatic senescence, are present in the YG8R mouse model of Friedreich's ataxia

    DMM Disease Models and Mechanisms, Vol. 9, Núm. 6, pp. 647-657

2015

  1. <i>Caenorhabditis elegans</i> Models to Study the Molecular Biology of Ataxias

    MOVEMENT DISORDERS: GENETICS AND MODELS, 2ND EDITION (ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD), pp. 1043-1059